MCID: ATR011
MIFTS: 65

Atrial Fibrillation

Categories: Cardiovascular diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Atrial Fibrillation

MalaCards integrated aliases for Atrial Fibrillation:

Name: Atrial Fibrillation 12 29 52 41 3 42 14 69
a-Fib 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060224
ICD10 33 I48
ICD9CM 35 427.31
MeSH 42 D001281
NCIt 47 C50466
UMLS 69 C0004238

Summaries for Atrial Fibrillation

MedlinePlus : 41 an arrhythmia is a problem with the speed or rhythm of the heartbeat. atrial fibrillation (af) is the most common type of arrhythmia. the cause is a disorder in the heart's electrical system. often, people who have af may not even feel symptoms. but you may feel palpitations -- an abnormal rapid heartbeat shortness of breath weakness or difficulty exercising chest pain dizziness or fainting fatigue confusion af can lead to an increased risk of stroke. in many patients, it can also cause chest pain, heart attack, or heart failure. doctors diagnose af using family and medical history, a physical exam, and a test called an electrocardiogram (ekg), which looks at the electrical waves your heart makes. treatments include medicines and procedures to restore normal rhythm. nih: national heart, lung, and blood institute

MalaCards based summary : Atrial Fibrillation, also known as a-fib, is related to atrial fibrillation, familial, 13 and atrial fibrillation, familial, 3, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Atrial Fibrillation is KCNQ1 (Potassium Voltage-Gated Channel Subfamily Q Member 1), and among its related pathways/superpathways are G-Beta Gamma Signaling and Vascular smooth muscle contraction. The drugs Amiodarone and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and lung, and related phenotypes are cardiovascular system and homeostasis/metabolism

CDC : 3 Electrical activity of a normal heart (left) and a heart with atrial fibrillation (right).

Disease Ontology : 12 A heart conduction disease that is characterized by uncoordinated electrical activity in the heart's upper chambers (the atria), which causes the heartbeat to become fast and irregular and has symptoms palpitations, weakness, fatigue, lightheadedness, dizziness, confusion, shortness of breath and chest pain.

Wikipedia : 72 Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm characterized by rapid and irregular... more...

Related Diseases for Atrial Fibrillation

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 6 Atrial Fibrillation, Familial, 11
Atrial Fibrillation, Familial, 10 Atrial Fibrillation, Familial, 5
Atrial Fibrillation 15 Atrial Fibrillation, Familial, 2
Atrial Fibrillation, Familial, 1 Atrial Fibrillation, Familial, 3
Atrial Fibrillation, Familial, 14 Atrial Fibrillation, Familial, 7
Atrial Fibrillation, Familial, 12 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 18 Atrial Fibrillation, Familial, 9
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 4
Familial Atrial Fibrillation Kcne5-Related Atrial Fibrillation
Nppa-Related Familial Atrial Fibrillation 6 Abcc9-Related Familial Atrial Fibrillation
Gja5-Related Familial Atrial Fibrillation Kcna5-Related Familial Atrial Fibrillation
Kcne2-Related Familial Atrial Fibrillation Kcnj2-Related Familial Atrial Fibrillation
Kcnq1-Related Familial Atrial Fibrillation Myl4-Related Familial Atrial Fibrillation
Scn1b-Related Familial Atrial Fibrillation Scn2b-Related Familial Atrial Fibrillation
Scn3b-Related Familial Atrial Fibrillation Scn5a-Related Familial Atrial Fibrillation

Diseases related to Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 295)
id Related Disease Score Top Affiliating Genes
1 atrial fibrillation, familial, 13 34.9 SCN1B SCN5A
2 atrial fibrillation, familial, 3 34.7 KCNE2 KCNQ1 SCN4B SCN5A
3 atrial fibrillation, familial, 10 34.5 KCNQ1 SCN2B SCN3B SCN4B SCN5A
4 short qt syndrome 1 32.6 KCNE2 KCNJ2 KCNQ1 SCN5A
5 third-degree atrioventricular block 31.0 GJA5 SCN5A
6 familial atrial fibrillation 12.5
7 atrial fibrillation, familial, 7 12.3
8 atrial fibrillation, familial, 12 12.3
9 atrial fibrillation, familial, 6 12.3
10 atrial fibrillation, familial, 11 12.3
11 atrial fibrillation, familial, 9 12.3
12 atrial fibrillation, familial, 4 12.3
13 atrial fibrillation 15 12.3
14 atrial fibrillation, familial, 14 12.3
15 atrial fibrillation and stroke 12.3
16 atrial fibrillation, familial, 18 12.2
17 atrial fibrillation, familial, 5 12.2
18 atrial fibrillation, familial, 2 12.2
19 atrial fibrillation, familial, 8 12.2
20 atrial fibrillation, familial, 1 12.2
21 kcne2-related familial atrial fibrillation 11.9
22 kcnj2-related familial atrial fibrillation 11.9
23 kcnq1-related familial atrial fibrillation 11.9
24 myl4-related familial atrial fibrillation 11.9
25 scn1b-related familial atrial fibrillation 11.9
26 scn2b-related familial atrial fibrillation 11.9
27 scn3b-related familial atrial fibrillation 11.9
28 scn5a-related familial atrial fibrillation 11.9
29 nppa-related familial atrial fibrillation 6 11.9
30 abcc9-related familial atrial fibrillation 11.9
31 gja5-related familial atrial fibrillation 11.9
32 kcna5-related familial atrial fibrillation 11.9
33 kcne5-related atrial fibrillation 11.9
34 long qt syndrome-10 11.7
35 brugada syndrome 7 11.7
36 pulmonary vein stenosis 11.3
37 short qt syndrome 3 11.2
38 rheumatic fever 11.2
39 coumarin resistance 11.1
40 mcleod syndrome with or without chronic granulomatous disease 11.0
41 chronic beryllium disease 11.0 GJA5 NPPA SCN5A
42 familial thoracic aortic aneurysm and dissection 11.0 SCN1B SCN5A
43 atrial standstill, digenic 11.0 GJA5 SCN1B SCN5A
44 ventricular fibrillation, familial, 1 11.0 GJA5 SCN5A
45 mental retardation, autosomal dominant 11 11.0 KCNE2 KCNQ1 SCN5A
46 thyroid lymphoma 11.0 GJA5 SCN1B SCN5A
47 brugada syndrome 1 10.9 KCNE2 KCNQ1 SCN5A
48 sick sinus syndrome 1 10.9 KCNE2 KCNQ1 SCN5A
49 sick sinus syndrome 2 10.9
50 syne1-related emery-dreifuss muscular dystrophy 10.9 KCNJ2 KCNQ1 SCN5A

Graphical network of the top 20 diseases related to Atrial Fibrillation:



Diseases related to Atrial Fibrillation

Symptoms & Phenotypes for Atrial Fibrillation

UMLS symptoms related to Atrial Fibrillation:


angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Atrial Fibrillation:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 NPPA NUP155 SCN3B SCN5A VKORC1 ABCC9
2 homeostasis/metabolism MP:0005376 9.77 ABCC9 ACE ADRB1 GJA5 KCNA5 KCNE2
3 muscle MP:0005369 9.28 ABCC9 ADRB1 GJA5 HCN4 KCNA5 KCNJ2

Drugs & Therapeutics for Atrial Fibrillation

Drugs for Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 492)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiodarone Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 1951-25-3 2157
2
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
3
Propafenone Approved Phase 4,Phase 3,Phase 2,Phase 1 54063-53-5 4932
4
Sotalol Approved Phase 4,Phase 3,Phase 2,Phase 1 959-24-0, 3930-20-9 5253
5
Menthol Approved Phase 4,Phase 3,Phase 2 2216-51-5 16666
6
Diltiazem Approved Phase 4,Phase 3,Phase 1 42399-41-7 39186
7
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
8
Rivaroxaban Approved Phase 4,Phase 3,Phase 2,Phase 1 366789-02-8
9
Ticagrelor Approved Phase 4,Phase 3,Phase 1 274693-27-5 9871419
10
Warfarin Approved Phase 4,Phase 3,Phase 2 81-81-2 6691 54678486
11
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
12
Acenocoumarol Approved Phase 4,Phase 3,Phase 2 152-72-7 9052 54676537
13
Salicylic acid Approved, Vet_approved Phase 4,Phase 3 69-72-7 338
14
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
15
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
16
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
17
Enfuvirtide Approved, Investigational Phase 4 159519-65-0 16130199
18
Phenprocoumon Approved Phase 4,Phase 3 435-97-2 9908 54680692
19
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
20
Amlodipine Approved Phase 4 88150-42-9 2162
21
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
22
Simvastatin Approved Phase 4,Phase 2 79902-63-9 54454
23
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
24
Ranolazine Approved, Investigational Phase 4,Phase 2,Phase 3 142387-99-3, 95635-55-5 56959
25
Ibutilide Approved Phase 4 122647-32-9, 122647-31-8 60753
26
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 37350-58-6, 51384-51-1 4171
27
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2 58-61-7 60961
28
Digoxin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-75-5 30322 2724385
29
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 772 46507594
30
Dalteparin Approved Phase 4,Phase 3,Phase 2 9005-49-6
31
Procainamide Approved Phase 4,Phase 3 51-06-9 4913
32
Thrombin Approved Phase 4,Phase 2,Phase 3,Phase 1
33
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
34
Sevoflurane Approved, Vet_approved Phase 4,Phase 1,Phase 2 28523-86-6 5206
35
Bisoprolol Approved Phase 4,Early Phase 1 66722-44-9 2405
36
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
37
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
38
Colchicine Approved Phase 4,Phase 3,Phase 2 64-86-8 6167 2833
39
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
40
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
41
Ephedrine Approved Phase 4 299-42-3 9294
42
Oxymetazoline Approved Phase 4,Phase 2 1491-59-4 4636
43
Phenylephrine Approved Phase 4,Phase 2 59-42-7 6041
44
Pseudoephedrine Approved Phase 4 90-82-4 7028
45
Iron Approved Phase 4,Phase 3 7439-89-6 23925
46
Nitroglycerin Approved, Investigational Phase 4,Phase 3 55-63-0 4510
47
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 2078-54-8 4943
48
Losartan Approved Phase 4,Phase 3 114798-26-4 3961
49
Nifedipine Approved Phase 4 21829-25-4 4485
50
Dofetilide Approved Phase 4,Phase 3 115256-11-6 71329

Interventional clinical trials:

(show top 50) (show all 2013)

id Name Status NCT ID Phase Drugs
1 Cardioversion vs. Catheter Ablation for Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
2 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4 Amiodarone
3 Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor Unknown status NCT01694394 Phase 4
4 Line Versus Spot Ablation in Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
5 AF Ablation With or Without ROX Coupler Study Unknown status NCT02243891 Phase 4
6 Atrial Fibrillation and the Risk for Neurological Complications Unknown status NCT00357227 Phase 4
7 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study: The LAAPITUP 2 Study Unknown status NCT01504451 Phase 4
8 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
9 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
10 Vernakalant Versus Flecainide: Atrial Contractility Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
11 Efficacy and Safety Study of Catheter Ablation for Atrial Fibrillation Unknown status NCT01113294 Phase 4
12 Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
13 Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
14 DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation Unknown status NCT01468155 Phase 4 dabigatran
15 Pulmonary Vein (PV) -Isolation: Arrhythmogenic Vein(s) Versus All Veins Unknown status NCT00605748 Phase 4
16 Low Dose of Diltiazem for Rate Control of Atrial Fibrillation Unknown status NCT00834925 Phase 4 low dose diltiazem
17 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
18 Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban Unknown status NCT02549963 Phase 4 Rivaroxaban
19 Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
20 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
21 A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
22 EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography Unknown status NCT01371279 Phase 4
23 Irbesartan and Adhesion Molecules in AF Unknown status NCT00613496 Phase 4 irbesartan;placebo
24 Anticoagulation in Stent Intervention Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
25 Mode Evaluation in Sick Sinus Syndrome Trial (MODEST) Unknown status NCT00161551 Phase 4
26 Corticosteroid Pulse After Ablation Unknown status NCT00807586 Phase 4 Solumedrol;Placebo
27 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
28 Catheter Contact Force and Electrograms Unknown status NCT01587404 Phase 4
29 Ventricular Pacing Site Selection (V-PASS) Unknown status NCT00292383 Phase 4
30 The Efficacy and Safety of CARTO 3D Mapping System Versus Conventional Method in AF and VT Unknown status NCT00959205 Phase 4
31 Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation Unknown status NCT00776633 Phase 4 aspirin;clopidogrel;oral anticoagulation
32 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
33 The Study of Warfarin Maintenance Dose in Chinese Patients Unknown status NCT01855737 Phase 4 Warfarin
34 RAAS Inhibitor Drugs in Dialysis Patients Unknown status NCT01635387 Phase 4 aliskiren
35 Right Ventricular Septal Pacing for the Prevention of Left Ventricular Dysfunction in Patients With Atrio-Ventricular Block Unknown status NCT00709774 Phase 4
36 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
37 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
38 Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients Unknown status NCT01394770 Phase 4 Aliskiren
39 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
40 Safety of Amiodarone and Ranolazine Together in Patients With Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
41 Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controled Trial Unknown status NCT02211053 Phase 4 Levothyroxine;placebo
42 Steroids In caRdiac Surgery Trial (SIRS Trial) Unknown status NCT00427388 Phase 4 Methylprednisolone
43 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit Completed NCT01461733 Phase 4 amiodarone;Placebo
44 Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation Completed NCT00863213 Phase 4 Antiarrhythmic drug
45 Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF Completed NCT01435161 Phase 4 Nifedipine,;Telmisartan
46 A New Approach to Target the Substrates of Persistent Atrial Fibrillation: The Sequential Substrate Ablation Approach Completed NCT02654353 Phase 4
47 Withdrawal Versus Continuation of Amiodarone in Successfully Treated Patients With Persistent Atrial Fibrillation Completed NCT00845780 Phase 4 withdrawal or continuation of amiodarone therapy
48 Atrial Fibrillation and Congestive Heart Failure Trial Completed NCT00597077 Phase 4
49 Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery Completed NCT00127712 Phase 4 Amiodarone
50 Ablation of the Pulmonary Veins for Paroxysmal Afib Completed NCT00744874 Phase 4

Search NIH Clinical Center for Atrial Fibrillation

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: atrial fibrillation

Genetic Tests for Atrial Fibrillation

Genetic tests related to Atrial Fibrillation:

id Genetic test Affiliating Genes
1 Atrial Fibrillation 29

Anatomical Context for Atrial Fibrillation

MalaCards organs/tissues related to Atrial Fibrillation:

39
Heart, Testes, Lung, Brain, Endothelial, Kidney, Bone

Publications for Atrial Fibrillation

Articles related to Atrial Fibrillation:

(show top 50) (show all 2330)
id Title Authors Year
1
Decreased Mortality With Beta-Blockers inA Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy. ( 28089316 )
2017
2
Atrial fibrillation associated with Wolff-Parkinson-White syndrome in a patient with concomitant Brugada syndrome. ( 28491758 )
2017
3
Analysis of Circulating miR-1, miR-23a, and miR-26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery. ( 28422282 )
2017
4
Shifting Perceptions of Risk and Reward: Use of Anticoagulation in Patients With Acute Brain Ischemia and Atrial Fibrillation: Nine-Year Data From a National Acute Stroke Registry (National Acute Stroke Israeli Survey [NASIS]). ( 28258255 )
2017
5
Comparison of Pulmonary Venous and Left Atrial Remodeling in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy Versus With Hypertensive Heart Disease. ( 28214001 )
2017
6
Pro-atrial natriuretic peptide and prediction of atrial fibrillation and stroke: The MalmAP Preventive Project. ( 28195503 )
2017
7
Association between subjective risk perception and objective risk estimation in patients with atrial fibrillation: a cross-sectional study. ( 28951417 )
2017
8
The APPLE Score - A Novel Score for the Prediction of Rhythm Outcomes after Repeat Catheter Ablation of Atrial Fibrillation. ( 28085921 )
2017
9
Fall risk and anticoagulation for atrial fibrillation in the elderly: A delicate balance. ( 28084982 )
2017
10
Esophageal Injury and Atrioesophageal Fistula Caused by Ablation for Atrial Fibrillation. ( 28947480 )
2017
11
Over 15% of atrial fibrillation patients are not prescribed any antithrombotic agent for stroke prevention by GPs. ( 28951426 )
2017
12
Association of serum chemerin concentrations with the presence of atrial fibrillation. ( 27496791 )
2017
13
Atrial fibrillation and stroke as initial manifestations of painless type A aortic dissection. ( 28803639 )
2017
14
Refining Prediction of Atrial Fibrillation Risk in the General Population With Analysis of P-Wave Axis (from the Atherosclerosis Risk in Communities Study). ( 28941601 )
2017
15
Recurrent haemoptysis as a symptom of severe pulmonary vein stenosis-a rare complication of catheter ablation in atrial fibrillation. ( 28096996 )
2017
16
Circulating intermediate CD14++CD16+monocytes are increased in patients with atrial fibrillation and reflect the functional remodelling of the left atrium. ( 26826137 )
2017
17
Oncostatin M was associated with thrombosis in patients with atrial fibrillation. ( 28471981 )
2017
18
Letter by Jin-shan and Xue-bin Regarding Article, "Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control])". ( 28947485 )
2017
19
Familial clustering of atrial fibrillation and comparative longitudinal outcomes of familial and non-familial atrial fibrillation. ( 28485191 )
2017
20
Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy. ( 28947201 )
2017
21
Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. ( 28938960 )
2017
22
Role of the MAPKs/TGF-I^1/TRAF6 signaling pathway in postoperative atrial fibrillation. ( 28323847 )
2017
23
Clinical utility and functional analysis of variants in atrial fibrillation-associated locus 4q25. ( 28087289 )
2017
24
Risk of stroke in congestive heart failure with and without atrial fibrillation. ( 28826798 )
2017
25
Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. ( 28950373 )
2017
26
The importance of atrial fibrillation in the pathogenesis of right ventricular failure following left ventricular assist device therapy. ( 28948672 )
2017
27
Some light in the shadows of atrial fibrillation and stroke: To look or not to look. ( 28904089 )
2017
28
Hyperglycemia on admission and hospitalization outcomes in patients with atrial fibrillation. ( 28898432 )
2017
29
Pacemaker-detected severe sleep apnea predicts new-onset atrial fibrillation. ( 28073884 )
2017
30
Correction to: Severe Pulmonary Vein Stenosis Resulting From Ablation for Atrial Fibrillation: Presentation, Management, and Clinical Outcomes. ( 28461425 )
2017
31
Left atrial appendage occlusion in a patient with hereditary hemorrhagic telangiectasia and atrial fibrillation - a therapeutic option worth considering. ( 28905045 )
2017
32
The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution. ( 28737773 )
2017
33
Prognostic Impact of Atrial Fibrillation and New Risk Score of Its Onset in Patients at High Risk of Heart Failurea88- A Report From the CHART-2 Study. ( 28090009 )
2017
34
New-onset atrial fibrillation after percutaneous coronary intervention with stent: Updated proposal of an algorithm for the choice of oral anticoagulant and its dose. ( 28087220 )
2017
35
Letter by Jazayeri et al Regarding Article, "Severe Pulmonary Vein Stenosis Resulting From Ablation for Atrial Fibrillation: Presentation, Management, and Clinical Outcomes". ( 28461423 )
2017
36
Atrial fibrillation and hyperthyroidism: A literature review. ( 28822529 )
2017
37
Incidence of atrial fibrillation detected by continuous rhythm monitoring after acute myocardial infarction in patients with preserved left ventricular ejection fraction: results of the ARREST study. ( 28069838 )
2017
38
Response by Fender et al to Letter Regarding Article, "Severe Pulmonary Vein Stenosis Resulting From Ablation for Atrial Fibrillation: Presentation, Management, and Clinical Outcomes". ( 28461424 )
2017
39
Effect of ramipril/hydrochlorothiazide and ramipril/canrenone combination on atrial fibrillation recurrence in hypertensive type 2 diabetic patients with and without cardiac autonomic neuropathy. ( 28507568 )
2017
40
Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble. ( 28264920 )
2017
41
The Global Burden of Atrial Fibrillation andA Stroke: A Systematic Review of the Clinical Epidemiology of Atrial FibrillationA inA Asia. ( 28427968 )
2017
42
Ethanol injection into the Marshall vein provoking a pericardial effusion resulting in a fatal complication in a patient with persistent atrial fibrillation. ( 28878915 )
2017
43
Left Atrial Mechanical Function and Aortic Stiffness in Middle-aged Patients with the First Episode of Atrial Fibrillation. ( 28091404 )
2017
44
Gain-of-function mutations in GATA6 lead to atrial fibrillation. ( 27756709 )
2017
45
Effect of Interleukin-27 Genetic Variants on Atrial Fibrillation Susceptibility. ( 28055231 )
2017
46
Predominant obstructive or central sleep apnea in patients with atrial fibrillation: influence of characterizing apneas versus apneas and hypopneas. ( 28899542 )
2017
47
Atrial fibrillation in retinal vascular occlusion disease and non-arteritic anterior ischemic optic neuropathy. ( 28771491 )
2017
48
Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets. ( 28948002 )
2017
49
Patients' and physicians' perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review. ( 28086887 )
2017
50
Screening for Atrial Fibrillation using Economical and accurate TechnologY (SAFETY)-a pilot study. ( 28087552 )
2017

Variations for Atrial Fibrillation

ClinVar genetic disease variations for Atrial Fibrillation:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 KCNQ1 NM_000218.2(KCNQ1): c.418A> G (p.Ser140Gly) single nucleotide variant Pathogenic rs120074192 GRCh37 Chromosome 11, 2549189: 2549189
2 SCN5A NM_000335.4(SCN5A): c.1410C> G (p.Asn470Lys) single nucleotide variant Pathogenic rs199473115 GRCh37 Chromosome 3, 38646328: 38646328
3 SCN5A NM_198056.2(SCN5A): c.1963G> A (p.Glu655Lys) single nucleotide variant Pathogenic/Likely pathogenic rs199473579 GRCh37 Chromosome 3, 38640469: 38640469
4 KCNQ1 NM_000218.2(KCNQ1): c.421G> A (p.Val141Met) single nucleotide variant Pathogenic/Likely pathogenic rs199472687 GRCh37 Chromosome 11, 2549192: 2549192
5 KCNQ1 NM_000218.2(KCNQ1): c.625T> C (p.Ser209Pro) single nucleotide variant Pathogenic rs199472705 GRCh37 Chromosome 11, 2592575: 2592575

Expression for Atrial Fibrillation

Search GEO for disease gene expression data for Atrial Fibrillation.

Pathways for Atrial Fibrillation

Pathways related to Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 16)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 SCN1B SCN2B SCN3B SCN4B SCN5A
2
Show member pathways
12.69 ADRB1 KCNJ2 KCNQ1 MYL4 NPPB SCN1B
3
Show member pathways
12.48 SCN1B SCN2B SCN3B SCN4B SCN5A
4
Show member pathways
12.42 ABCC9 KCNE2 KCNJ2 KCNQ1 MYL4 NPPA
5 12.36 ADRB1 SCN1B SCN2B SCN5A
6 12.18 KCNA5 KCNE2 KCNJ2 KCNQ1
7
Show member pathways
12 ADRB1 KCNE2 KCNJ2 KCNQ1
8 11.97 KCNQ1 SCN3B SCN4B SCN5A
9
Show member pathways
11.97 ABCC9 HCN4 KCNA5 KCNJ2 KCNQ1
10
Show member pathways
11.86 SCN1B SCN2B SCN3B SCN4B SCN5A
11
Show member pathways
11.57 KCNE2 KCNQ1 SCN1B SCN2B SCN3B SCN4B
12 11.5 ACE ADRB1 KCNJ2
13 11.18 ABCC9 ADRB1 GJA5 HCN4 KCNA5 KCNE2
14 11.13 SCN1B SCN2B SCN3B SCN4B SCN5A
15 10.9 NPPA NPPB
16 10.89 HCN4 KCNJ2 KCNQ1

GO Terms for Atrial Fibrillation

Cellular components related to Atrial Fibrillation according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Z disc GO:0030018 9.61 KCNA5 SCN3B SCN5A
2 voltage-gated potassium channel complex GO:0008076 9.55 ABCC9 KCNA5 KCNE2 KCNJ2 KCNQ1
3 T-tubule GO:0030315 9.5 KCNJ2 SCN1B SCN5A
4 intercalated disc GO:0014704 9.43 GJA5 KCNA5 KCNJ2 SCN1B SCN4B SCN5A
5 voltage-gated sodium channel complex GO:0001518 9.02 SCN1B SCN2B SCN3B SCN4B SCN5A
6 membrane GO:0016020 10.31 ABCC9 ACE ADRB1 GJA5 HCN4 KCNA5
7 plasma membrane GO:0005886 10.18 ABCC9 ACE ADRB1 GJA5 HCN4